WallStSmart

Merck & Company Inc (MRK)vsNano X Imaging Ltd (NNOX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 452941% more annual revenue ($65.77B vs $14.52M). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

NNOX

Hold

37

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 6.7Quality: 6.5
Piotroski: 2/9Altman Z: -0.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-62.3%)

Margin of Safety

-62.3%

Fair Value

$81.23

Current Price

$129.79

$48.56 premium

UndervaluedFair: $81.23Overvalued
NNOXUndervalued (+50.1%)

Margin of Safety

+50.1%

Fair Value

$4.49

Current Price

$0.88

$3.61 discount

UndervaluedFair: $4.49Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$307.25B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

NNOX3 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
53.1%10/10

Revenue surging 53.1% year-over-year

Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
35.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NNOX4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$61.67M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : NNOX

The strongest argument for NNOX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 53.1% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : NNOX

The primary concerns for NNOX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

MRK profiles as a value stock while NNOX is a hypergrowth play — different risk/reward profiles.

NNOX carries more volatility with a beta of 1.23 — expect wider price swings.

NNOX is growing revenue faster at 53.1% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 37/100). NNOX offers better value entry with a 50.1% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Nano X Imaging Ltd

HEALTHCARE · MEDICAL DEVICES · USA

Nano-X Imaging Ltd., a development-stage company, develops, produces and markets digital X-ray source technology for the medical imaging industry globally. The company is headquartered in Neve Ilan, Israel.

Visit Website →

Want to dig deeper into these stocks?